Korify Capital
VC Fund
Korify Capital is a VC fund focused on Biotechnology and Life Science. The firm has a strong focus on the biotech sector in the United States, Europe and Israel, but also selectively invests in fintech and blockchain opportunities.
- Total investments:
- 24
- Last investment:
- Lead investor:
- 4%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Korify Capital invests in
Stages Korify Capital invests in
Countries Korify Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Seed
- $4M–$15M
- Series A
- $10M–$165M
- Series B
- $30M–$60M
Investment Focus
Industry
- Biotechnology 7 (29%)
- Life Science 5 (21%)
- Biopharma 4 (17%)
- Health Care 4 (17%)
- Medical 3 (13%)
Stage
- Series A 7 (29%)
- Series B 5 (21%)
- Seed 3 (13%)
- Series C 2 (8%)
- Venture - Series Unknown 2 (8%)
Country
- United States 7 (29%)
- Germany 3 (13%)
- Switzerland 2 (8%)
- Mexico 1 (4%)
- Australia 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Davide Ottolini
Co-Founder, General Partner
|
Co-Founder, General Partner | Total investments: 0 | Find email | |
Marc Penkala
Adivsory Board Member
|
Adivsory Board Member | Total investments: 5 | Find email | |
Robin Lauber
Co-Founder, General Partner
|
Co-Founder, General Partner | Total investments: 3 | Find email | |
|
Sean Lauber
Co-Founder
|
Co-Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Wonder brands
|
Wonder Brands is a Latin American startup specialized in partnering with successful digital brands to boost their growth. The implementation of its strategy is achieved by injecting into associated companies a significant investment to exponentially increase working capital, marketing and equipment, as well as providing added value in the areas oftechnology, digital marketing, supply chain and administration. | $15.5M / Series A / Aug 17, 2023 | |
AERA Health
|
AERA Health is a start-up in preventive health technology. The mission is to motivate the next generation of healthcare professionals to realise their full potential and make a positive difference in the world. | $4.3M / Pre-Seed / Mar 20, 2023 | |
Bionomics
|
Bionomics Limited engages in the discovery and development of therapeutics for cancer and diseases of the central nervous system in Australia. It has small molecule product development programs in the areas of cancer, anxiety, epilepsy, and multiple sclerosis. The company develops its lead cancer compound, BNC 105, for the treatment of solidtumors, such as breast, lung, colon, and prostate cancers. BNC 105 is a member of the class of compounds, known as vascular disruption agents or VDAs, which shut down the blood supply within a tumor, starving the tumor and preventing its continued growth.The company has commercial partnerships with Genmab A/S; Athena Diagnostics; Laboratory Corporation of America; and Genetic Technologies, Ltd. Bionomics Limited was founded in 1999 and is based in Thebarton, Australia. | $5M / Post-IPO Equity / Nov 21, 2022 | |
Alto Neuroscience
|
Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develophighly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most. | $35M / Series B / Oct 25, 2022 | |
FORME
|
FORME Life has introduced a home exercise system. | $69.9M / Series A / Sep 29, 2022 | |
Gameto
|
Gameto is a biotechnology company whose mission is to redefine female reproductive health by developing therapies that improve lives.Women’s health is a vastly underserved therapeutic area. Most conditions have few treatment options, and those available often cause frequent complications and offer limited clinical benefit. Gameto aims to changethat.Gameto is committed to using cutting-edge scientific advances to deliver better solutions to patients. Using cellular engineering, they have developed a platform to produce female reproductive cell lines. They use proprietary combinations of transcription factors to reprogram hiPSCs into engineered ovarian and endometrium cell lines that mimic the functions of endogenous cells, producing and responding to all hormones. Their team of cellular engineers is using this platform to advance a portfolio of cellular therapeutics for female reproductive diseases. Gameto's first program, Fertilo, is a therapeutic for IVF and egg freezing, aiming to make the process shorter, safer and more effective. Additional applications of our platform include, an organoid of the female reproductive system, Deovo, and a cell-based therapeutic to ameliorate the health consequences of primary ovarian insufficiency and menopause, Ameno. | $17M / Venture - Series Unknown / Sep 14, 2022 | |
AMZSCALE
|
AMZSCALE experts whose knowledge comes from practice. Their team consists exclusively of experienced eCommerce experts who have built their own successful Amazon brands and some have already sold them. | Series A / Apr 25, 2022 | |
Storypod
|
Storypod helps parents, grandparents, and educators ignite children’s love of learning through screen-free, interactive audio edutainment. Our kid-safe, IoT audio platform leverages data-insights to provide stage-based content to help caretakers raise smart, healthy, and resilient kids. | $4M / Seed / Jan 26, 2022 | |
Cambrian Biopharma
|
Cambrian Biopharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health.As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is todevelop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age. | $100M / Series C / Oct 26, 2021 | |
Olsam Group
|
Olsam Group is a technology-driven commerce company that acquires and operates top Amazon third-party and other D2C eCommerce brands at scale. | $165M / Series A / Sep 01, 2021 | |
| See all 24 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Korify Capital invest in?
Korify Capital invests primarily in Biotechnology, Life Science and Biopharma startups, most often at Series A and Series B stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Korify Capital's check size?
Korify Capital typically joins rounds of $4M–$15M at Seed, $10M–$165M at Series A and $30M–$60M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Korify Capital participates in.
How do I contact Korify Capital?
Public channels for Korify Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Korify Capital?
The team at Korify Capital includes Davide Ottolini (Co-Founder, General Partner), Marc Penkala (Adivsory Board Member) and Robin Lauber (Co-Founder, General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
